RNWL
INTERNATIONAL REGISTRATION RENEWED
10/31/2024
Back to search
Official data from USPTO
ACACIA PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
10/31/2024
Trademark type
Combined
Nice classes
5, 42
Filing date
01/06/2015
Registration date
06/21/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/21/2016
Last transaction
08/05/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
GB
Examiner
PINO, BRIAN
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "ACACIA PHARMA" and the stylized design of an irregular oval shape with a block positioned above it that has a pointed end at the left edge and a flat end at the right edge. The design and word "ACACIA" are in black and the word "PHARMA" is in blue. The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
Acacia Pharma Limited
Representatives
Karl M. Zielaznicki, Esq. Troutman Pepper Hamilton Sanders LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Sanitary preparations for medical purposes; pharmaceutical preparations for the management of post-operative nausea and vomiting (PONV); pharmaceutical preparations for the management of chemotherapy induced nausea and vomiting (CINV); pharmaceutical preparations for the management of xerostomia (dry mouth); pharmaceutical preparations for the management of cancer cachexia; pharmaceutical preparations for the management of cancer treatment side effects; pharmaceutical preparations for the management of side effects of surgery; pharmaceutical preparations for the management of cancer side effects; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations associated with surgery
Class 42
Scientific and technological services and research and design relating theretoscientific researchanalysis and testing in the field of repurposing existing drugs for new therapeutic uses; pharmaceutical and veterinary product evaluationdevelopment and testing services; pharmaceutical researchinspection and testing; medical and pharmaceutical research services; scientific research for medical purposes in the area of cancerous disease; pharmaceutical researchinspectiontestingdevelopment and evaluation of pharmaceutical and veterinary preparationssanitary preparations for medical purposesdietetic food and substances adapted for medical or veterinary usepharmaceutical preparations for the management of post-operative nausea and vomiting (PONV)pharmaceutical preparations for the management of chemotherapy induced nausea and vomiting (CINV)pharmaceutical preparations for the management of xerostomia (dry mouth)pharmaceutical preparations for the management of cancer cachexiapharmaceutical preparations for the management of cancer treatment side effectspharmaceutical preparations for the management of side effects of surgerypharmaceutical preparations for the management of cancer side effectspharmaceutical preparations for the treatment of cancerpharmaceutical preparations associated with surgery; informationadvisory and consultancy services relating to the aforementioned services
Publications
History of USPTO decisions and trademark events.
41 publications found
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
10/11/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/25/2023
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
06/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/05/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/05/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/05/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/05/2022
ES71
TEAS SECTION 71 RECEIVED
06/06/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/18/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/21/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/12/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/12/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/12/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/12/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/30/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/11/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/20/2016
FIMP
FINAL DISPOSITION PROCESSED
10/20/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/21/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
06/21/2016
PUBO
PUBLISHED FOR OPPOSITION
04/05/2016
NPUB
NOTICE OF PUBLICATION
03/16/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/01/2016
ALIE
ASSIGNED TO LIE
02/23/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/11/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/11/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/11/2016
ALIE
ASSIGNED TO LIE
02/10/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/05/2016
RFNT
REFUSAL PROCESSED BY IB
10/24/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
10/08/2015
RFRR
REFUSAL PROCESSED BY MPU
10/08/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
10/08/2015
CNRT
NON-FINAL ACTION WRITTEN
10/07/2015
MAFR
APPLICATION FILING RECEIPT MAILED
10/06/2015
DOCK
ASSIGNED TO EXAMINER
10/02/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/02/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/01/2015
Continuous trademark protection
Get notified about every new filing that threatens ACACIA PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.